Literature DB >> 3895751

Myasthenia gravis--current concepts.

C Herrmann, J M Lindstrom, J C Keesey, D G Mulder.   

Abstract

An edited summary of an Interdepartmental Conference arranged by the Department of Medicine of the UCLA School of Medicine, Los Angeles. The Director of Conferences is William M. Pardridge, MD, Associate Professor of Medicine. Current findings indicate that autoimmune myasthenia gravis is an acquired immune complex disorder of neuromuscular transmission in voluntary striated muscle. There is a break in immunologic tolerance leading to blocking and degradation of acetylcholine receptors, together with widening of the synaptic cleft associated with partial destruction, simplification and shortening of the postjunctional membrane. Thymic hyperplasia and thymoma may be present. A decremental response to nerve-muscle stimulation, blocking and jitter on single-fiber electromyography and circulating antibodies to acetylcholine receptor are detectable in most patients with generalized weakness. Although the cause of this abnormal immunologic mechanism remains to be discovered, anticholinesterases, corticosteroids, immunosuppressants, plasmapheresis or thymectomy (individually or in combination) provide control and better prognosis in most patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3895751      PMCID: PMC1306182     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  105 in total

1.  Studies in myasthenia gravis. Correlation of antibody immunofluorescence with clinical course.

Authors:  K E Osserman; L B Weiner
Journal:  N Engl J Med       Date:  1965-09-16       Impact factor: 91.245

2.  Reappraisal of in vitro muscle biopsy in myasthenia gravis.

Authors:  C Herrmann; P B Sabawala; W F Barker; J B Dillon
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

3.  Primary structure of alpha-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence.

Authors:  M Noda; H Takahashi; T Tanabe; M Toyosato; Y Furutani; T Hirose; M Asai; S Inayama; T Miyata; S Numa
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

4.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

5.  Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor.

Authors:  B Conti-Tronconi; S Tzartos; J Lindstrom
Journal:  Biochemistry       Date:  1981-04-14       Impact factor: 3.162

Review 6.  Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model.

Authors:  J Lindstrom
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

7.  Biochemical properties of acteylcholine receptor subunits from Torpedo californica.

Authors:  J Lindstrom; J Merlie; G Yogeeswaran
Journal:  Biochemistry       Date:  1979-10-16       Impact factor: 3.162

8.  Computed tomography of the anterior mediastinum in myasthenia gravis. A radiologic-pathologic correlative study.

Authors:  G T Fon; M E Bein; A A Mancuso; J C Keesey; A R Lupetin; W S Wong
Journal:  Radiology       Date:  1982-01       Impact factor: 11.105

9.  Hypersensitivity of in vitro myasthenic muscle to d-tubocurarine.

Authors:  J B DILLON; P B SABAWALA
Journal:  Neurology       Date:  1959-01       Impact factor: 9.910

10.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

View more
  2 in total

Review 1.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

2.  Electrophysiological study in neuromuscular junction disorders.

Authors:  Ajith Cherian; Neeraj N Baheti; Thomas Iype
Journal:  Ann Indian Acad Neurol       Date:  2013-01       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.